Key points are not available for this paper at this time.
Abstract Background Despite increased use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma, little is known about patient experiences during this treatment. This study aimed to gain an in-depth understanding of experiences and unmet care needs of patients treated in the adjuvant or metastatic setting for advanced melanoma regarding their ICI treatment trajectory. Methods Interviews and focus groups were conducted among 35 patients treated with ICIs in the adjuvant setting for completely resected stage III ( n = 14), or in the metastatic setting for irresectable stage IV ( n = 21) melanoma. A thorough thematic content analysis was conducted. Results Three main themes were identified. When (1) dealing with uncertainty in the decision-making process , adjuvant patients explored the pros and cons, whereas metastatic patients considered immunotherapy their only viable option. Both groups expressed the need for additional guidance. In (2) navigating the immunotherapy course , both perceived the trajectory as intense, experienced a major impact on their and their (close) relatives’ lives, and felt the need to (re)gain control. When (3) looking back on the immunotherapy experience , metastatic patients generally felt relieved, while among adjuvant patients, feelings of doubt regarding their choice for ICIs were also reported. Conclusions ICI treatment is perceived as intensive for both patient groups, facing both comparable and distinct challenges throughout the treatment trajectory, underscoring the need for stage-specific, individualised guidance. Options regarding flexible follow-ups, low-threshold contact and psychosocial support throughout the treatment trajectory should be explored.
Kamminga et al. (Thu,) studied this question.